-
公开(公告)号：US20090087404A1
公开(公告)日：2009-04-02
申请号：US12250911
申请日：2008-10-14
申请人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
发明人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
-
公开(公告)号：US20110086004A1
公开(公告)日：2011-04-14
申请号：US12947957
申请日：2010-11-17
申请人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
发明人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
-
3.发明申请公开(公告)号：US20110300098A1
公开(公告)日：2011-12-08
申请号：US12826099
申请日：2010-06-29
申请人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
发明人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
摘要翻译： 描述了通过用IL-21共同施用治疗性单克隆抗体来治疗癌症的方法。 可以使用的示例性单克隆抗体是利妥昔单抗，曲妥珠单抗和抗CTLA-4抗体。 联合治疗的增强的抗肿瘤剂对于单克隆治疗顽固性，用单克隆抗体治疗后复发或增强的IL-21抗肿瘤作用降低与使用单克隆抗体治疗相关的毒性的患者群体特别有用。
-
4.发明授权Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide 失效使用哺乳动物组织纤溶酶原激活物分泌肽产生血小板生成素多肽的方法
公开(公告)号：US5641655A
公开(公告)日：1997-06-24
申请号：US347029
申请日：1994-11-30
IPC分类号： C12N15/09 , C07K14/47 , C07K14/52 , C12N1/19 , C12N5/10 , C12N9/72 , C12N15/62 , C12P21/02 , C12R1/865 , C12N15/19 , C07H21/04
CPC分类号： C12N9/6459 , C07K14/524 , C12N15/625 , C12Y304/21069 , C07K2319/02 , C07K2319/036 , C07K2319/50 , C07K2319/75
摘要： DNA constructs useful in the production of thrombopoietin are disclosed. In general, the DNA constructs comprise a first DNA segment encoding a fusion of an amino-terminal secretory peptide joined to a thrombopoietin polypeptide and one or more additional DNA segments that provide for the transcription of the first segment. The secretory peptide is a native mammalian t-PA secretory peptide or may be modified to enhance proteolytic cleavage of the fusion. Also disclosed are cultured eukaryotic cells containing these DNA constructs and methods for producing thrombopoietin polypeptides through the use of the DNA constructs and cultured eukaryotic cells.
摘要翻译： 公开了可用于生产血小板生成素的DNA构建体。 通常，DNA构建体包含编码与血小板生成素多肽连接的氨基末端分泌肽与提供第一片段转录的一个或多个另外的DNA片段的融合物的第一DNA片段。 分泌肽是天然哺乳动物的t-PA分泌肽，或可以被修饰以增强融合物的蛋白水解切割。 还公开了含有这些DNA构建体的培养真核细胞和通过使用DNA构建体和培养的真核细胞产生血小板生成素多肽的方法。
-
公开(公告)号：US5776725A
公开(公告)日：1998-07-07
申请号：US86631
申请日：1993-07-01
申请人： Wayne R. Kindsvogel , Laura J. Jelinek , Paul O. Sheppard , Francis J. Grant , Joseph L. Kuijper , Donald C. Foster , Si Lok , Patrick J. O'Hara
发明人： Wayne R. Kindsvogel , Laura J. Jelinek , Paul O. Sheppard , Francis J. Grant , Joseph L. Kuijper , Donald C. Foster , Si Lok , Patrick J. O'Hara
IPC分类号： C07K14/72 , C07K16/28 , C12N5/10 , C12N15/06 , C12N15/12 , C12N15/62 , C12Q1/66 , C12Q1/68 , G01N33/74
CPC分类号： C07K14/72 , C12Q1/66 , G01N33/74 , C07K2319/00 , C07K2319/02 , G01N2333/605 , G01N2333/72
摘要： The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs. The present invention also provides a method for detecting the presence of glucagon antagonists, comprising the steps of (a) exposing a compound in the presence of a glucagon against to a recombinant glucagon receptor coupled to a response pathway under conditions and for time sufficient to allow binding of the compound to the receptor and an associated response through the pathway, and (b) detecting a reduction in the stimulation of the response pathway resulting from the binding of the compound to the glucagon receptor, relative to the stimulation of the response pathway by the glucagon agonist alone and therefrom determining the presence of a glucagon antagonist.
摘要翻译： 本发明提供了分离的DNA分子，其包含编码胰高血糖素受体的DNA区段。 还提供了DNA构建体，其包含编码与第一DNA区段表达所需的另外的DNA区段可操作地连接的胰高血糖素受体的第一DNA区段，以及含有这种DNA构建体的宿主细胞。 本发明还提供了一种用于检测胰高血糖素拮抗剂的存在的方法，其包括以下步骤：（a）在条件和时间足以允许的情况下，在与胰岛素反应途径偶联的重组胰高血糖素受体上暴露化合物 化合物与受体的结合和通过途径的相关应答，以及（b）相对于刺激响应途径，检测由化合物与胰高血糖素受体的结合引起的反应途径的刺激减少 胰高血糖素激动剂单独和由此决定胰高血糖素拮抗剂的存在。
-
公开(公告)号：US5919635A
公开(公告)日：1999-07-06
申请号：US452930
申请日：1995-05-30
申请人： Wayne R. Kindsvogel , Laura J. Jelinek , Paul O. Sheppard , Francis J. Grant , Joseph L. Kuijper , Donald C. Foster , Si Lok , Patrick J. O'Hara
发明人： Wayne R. Kindsvogel , Laura J. Jelinek , Paul O. Sheppard , Francis J. Grant , Joseph L. Kuijper , Donald C. Foster , Si Lok , Patrick J. O'Hara
IPC分类号： G01N33/566 , A61K38/00 , C07H21/04 , C07K14/605 , C07K14/72 , C07K16/28 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/66 , C12Q1/68 , G01N33/50 , G01N33/74 , C07K14/705
CPC分类号： C07K14/723 , C07K14/72 , C12Q1/66 , G01N33/74 , A61K38/00 , C07K2319/00 , C07K2319/02 , G01N2333/605 , G01N2333/72
摘要： The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs. The present invention also provides a method for detecting the presence of glucagon antagonists, comprising the steps of (a) exposing a compound in the presence of a glucagon against to a recombinant glucagon receptor coupled to a response pathway under conditions and for time sufficient to allow binding of the compound to the receptor and an associated response through the pathway, and (b) detecting a reduction in the stimulation of the response pathway resulting from the binding of the compound to the glucagon receptor, relative to the stimulation of the response pathway by the glucagon agonist alone and therefrom determining the presence of a glucagon antagonist.
摘要翻译： 本发明提供了分离的DNA分子，其包含编码胰高血糖素受体的DNA区段。 还提供了DNA构建体，其包含编码与第一DNA区段表达所需的另外的DNA区段可操作地连接的胰高血糖素受体的第一DNA区段，以及含有这种DNA构建体的宿主细胞。 本发明还提供了一种用于检测胰高血糖素拮抗剂的存在的方法，其包括以下步骤：（a）在条件和时间足以允许的情况下，在与胰岛素反应途径偶联的重组胰高血糖素受体上暴露化合物 化合物与受体的结合和通过途径的相关应答，以及（b）相对于刺激响应途径，检测由化合物与胰高血糖素受体的结合引起的反应途径的刺激减少 胰高血糖素激动剂单独和由此决定胰高血糖素拮抗剂的存在。
-
公开(公告)号：US5770445A
公开(公告)日：1998-06-23
申请号：US453956
申请日：1995-05-30
申请人： Wayne R. Kindsvogel , Laura J. Jelinek , Paul O. Sheppard , Francis J. Grant , Joseph L. Kuijper , Donald C. Foster , Si Lok , Patrick J. O'Hara
发明人： Wayne R. Kindsvogel , Laura J. Jelinek , Paul O. Sheppard , Francis J. Grant , Joseph L. Kuijper , Donald C. Foster , Si Lok , Patrick J. O'Hara
IPC分类号： G01N33/566 , A61K38/00 , C07H21/04 , C07K14/605 , C07K14/72 , C07K16/28 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/66 , C12Q1/68 , G01N33/50 , G01N33/74
CPC分类号： C07K14/723 , C07K14/72 , C12Q1/66 , G01N33/74 , A61K38/00 , C07K2319/00 , C07K2319/02 , G01N2333/605 , G01N2333/72
摘要： The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs. The present invention also provides a method for detecting the presence of glucagon antagonists, comprising the steps of (a) exposing a compound in the presence of a glucagon against to a recombinant glucagon receptor coupled to a response pathway under conditions and for time sufficient to allow binding of the compound to the receptor and an associated response through the pathway, and (b) detecting a reduction in the stimulation of the response pathway resulting from the binding of the compound to the glucagon receptor, relative to the stimulation of the response pathway by the glucagon agonist alone and therefrom determining the presence of a glucagon antagonist.
摘要翻译： 本发明提供了分离的DNA分子，其包含编码胰高血糖素受体的DNA区段。 还提供了DNA构建体，其包含编码与第一DNA区段表达所需的另外的DNA区段可操作地连接的胰高血糖素受体的第一DNA区段，以及含有这种DNA构建体的宿主细胞。 本发明还提供了一种用于检测胰高血糖素拮抗剂的存在的方法，其包括以下步骤：（a）在条件和时间足以允许的情况下，在与胰岛素反应途径偶联的重组胰高血糖素受体上暴露化合物 化合物与受体的结合和通过途径的相关应答，以及（b）相对于刺激响应途径，检测由化合物与胰高血糖素受体的结合引起的反应途径的刺激减少 胰高血糖素激动剂单独和由此决定胰高血糖素拮抗剂的存在。
-
公开(公告)号：US08227575B2
公开(公告)日：2012-07-24
申请号：US12626307
申请日：2009-11-25
申请人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
发明人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
IPC分类号： C07K16/00 , A61K39/395 , A61K38/00 , C07K14/00 , C07K5/00
CPC分类号： C07K14/001 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K38/18 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/715 , C07K16/24 , C07K16/2866 , C07K2317/73 , C07K2319/00 , C07K2319/21 , C07K2319/24 , C07K2319/30 , C07K2319/55 , C12N15/62 , C12N15/8509 , C12N2799/026 , G01N2333/52 , A61K2300/00
摘要： Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
摘要翻译： 描述了与SEQ ID NO：2所示的包含zalpha11配体的序列的多肽和肽结合的抗体。 抗体可以结合162个氨基酸残基或其片段的全长序列，包括131个氨基酸残基的成熟多肽和较小的多肽和肽序列。 抗体可以包括多克隆，单克隆，鼠，人源化或中和的抗体。 还描述了产生抗体的方法。
-
公开(公告)号：US07626002B2
公开(公告)日：2009-12-01
申请号：US11532776
申请日：2006-09-18
申请人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
发明人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
IPC分类号： C07K16/00 , A61K39/395 , C07K14/00 , C07K5/00
CPC分类号： C07K14/001 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K38/18 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/715 , C07K16/24 , C07K16/2866 , C07K2317/73 , C07K2319/00 , C07K2319/21 , C07K2319/24 , C07K2319/30 , C07K2319/55 , C12N15/62 , C12N15/8509 , C12N2799/026 , G01N2333/52 , A61K2300/00
摘要： Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
摘要翻译： 描述了与SEQ ID NO：2所示的包含zalpha11配体的序列的多肽和肽结合的抗体。 抗体可以结合162个氨基酸残基或其片段的全长序列，包括131个氨基酸残基的成熟多肽和较小的多肽和肽序列。 抗体可以包括多克隆，单克隆，鼠，人源化或中和的抗体。 还描述了产生抗体的方法。
-
公开(公告)号：US07569670B2
公开(公告)日：2009-08-04
申请号：US11551368
申请日：2006-10-20
申请人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
发明人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
CPC分类号： C07K14/001 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K38/18 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/715 , C07K16/24 , C07K16/2866 , C07K2317/73 , C07K2319/00 , C07K2319/21 , C07K2319/24 , C07K2319/30 , C07K2319/55 , C12N15/62 , C12N15/8509 , C12N2799/026 , G01N2333/52 , A61K2300/00
摘要： Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
摘要翻译： 描述了与SEQ ID NO：2所示的包含zalpha11配体的序列的多肽和肽结合的抗体。 抗体可以结合162个氨基酸残基或其片段的全长序列，包括131个氨基酸残基的成熟多肽和较小的多肽和肽序列。 抗体可以包括多克隆，单克隆，鼠，人源化或中和的抗体。 还描述了产生抗体的方法。
-
-
-
-
-
-
-
-
-
搜索结果
89 条记录 (耗时 0.079 秒)
